BN Business News
기업 추가 →
이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.

규제 및 법률 · 2006. 11. 13.1 분 읽기

Prospective Grant of Exclusive License: Field of Use: Treatment of Inflammatory Diseases Using Ghrelin

로컬 자동 번역 · 원본 출처 언어

요약

This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license to practice the invention embodied in: U.S. Provisional Patent application, S/N 60/569,819 filed May 11, 2004, entitled "Methods for Inhibiting Proinflammatory Cytokine Expression Using Ghrelin," converted to PCT on May 11, 2005 (E-016- 2004/0-PCT-02), (Inventors: Vishwa D. Dixit, Dennis D. Taub, Eric Schaffer, and Dzung Nguyen) (NIA), to Sapphire Therapeutics, Inc. (Hereafter Sapphire), having a place of business in Bridgewater of NJ. The patent rights in these inventions have been assigned to the United States of America.

원본 출처 언어: Federal Register — All Documents원문 발표 열기 →